Related Experiment Video
Updated: Jul 4, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
Hannah Kinoshita1, Catherine M Bollard1, Keri Toner1
1Cell Enhancement and Technologies for Immunotherapy, Children's National Hospital, Washington, DC; Department of Pediatrics, George Washington University, Washington, DC.
Seminars in Hematology
|February 9, 2024
Summary
CAR-T cell therapy shows promise for diffuse large B cell lymphoma (DLBCL), but many patients relapse. This review explores factors contributing to CAR-T therapy failure in DLBCL, aiding future treatment strategies.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Chimeric antigen receptor T (CAR-T) cell therapy is approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL).
- Despite efficacy, a significant proportion of DLBCL patients (up to 60%) experience disease progression or relapse after CAR-T therapy.
- The complex mechanisms underlying resistance to CAR-T cell therapy in DLBCL remain incompletely understood.
Conclusions:
- CAR-T cell therapy for DLBCL faces challenges due to resistance mechanisms.
- Further research into predictive factors is necessary to optimize treatment outcomes.
- Identifying resistance factors will guide the development of more effective therapeutic strategies for DLBCL.
Related Concept Videos
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K